A single-dilution quantitative enzyme-linked immunosorbent assay (ELISA) system, based on commercial ELISA kits, for the simultaneous detection of seroconversion to bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), parainfluenza-3 virus (PI3V), and infectious bovine rhinotracheitis virus (IBRV) was evaluated by testing acute and convalescent serum pairs from 564 cattle in 145 outbreaks of respiratory disease. Seroconversion to BVDV, BRSV, PI3V and IBRV was detected in 8.0%, 19.0%, 13.7%, and 7.4%, respectively, of serum pairs tested. Seroconversion was detected in 60.7% of herds and 34.6% of animals tested. Infection with 2 or more viruses was found in 46.6% of these herds and in 27.2% of these animals. The majority of BVDV infections (62%) were associated with other virus infections, suggesting that BVDV may potentiate infection with other agents rather than being a primary pathogen of the respiratory tract. The results were compared with those obtained by virus neutralization and hemagglutination inhibition testing, and the sensitivity, specificity, and overall correlation were calculated. Sensitivities of 92%, 95%, 100%, and 100% were obtained for BVDV, BRSV, PI3V, and IBRV, respectively. The corresponding specificity values were 89%, 92%, 86%, and 91%. The overall correlation for each virus was 90%, 93%, 90%, and 93%, respectively. These results demonstrate that this ELISA system may be used successfully to detect seroconversion in serum pairs, highlight the frequency of multiple viral infections in outbreaks of respiratory disease, and provide further evidence of an immunosuppressive role for BVDV infections.
A single-dilution enzyme-linked immunosorbent assay (ELISA) system for quantifying antibody levels to bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), parainfluenza-3 virus (PI3V), and infectious bovine rhinotracheitis virus (IBRV) has previously been described. 9 This system is based on the standardization of commercially available kits and offers the potential for simultaneously testing acute and convalescent serum pairs for evidence of seroconversion to these 4 viruses. Such a system offers considerable savings over more labor-intensive tests, such as virus neutralization (VN), hemagglutination inhibition (HI), complement fixation, immunofluorescent antibody testing (IFAT), and ELISA end-point titration, that are conventionally used for testing serum pairs and that require testing of serial dilutions of each sample. 1, 23 The purpose of this work was to evaluate this ELI-SA system for the detection of seroconversion to BVDV, BRSV, PI3V, and IBRV by using it to test serum pairs submitted from 145 outbreaks of respiratory disease in cattle. To determine the sensitivity and specificity of the system, the results obtained were compared with the results of testing by VN and HI.
Material and methods
Bovine sera. Private veterinary practitioners were asked to submit paired acute and convalescent bovine sera from samples obtained 2-4 wk apart during field outbreaks of respiratory disease. A total of 564 serum pairs, from 145 outbreaks (x ϭ 3.90 pairs/outbreak; range ϭ 1-16 pairs), were submitted for examination between January 1994 and February 1996 and used for subsequent testing. Sera were stored at Ϫ20 C or below prior to testing. Those used in VN or HI testing were first heat inactivated at 56 C for 30 min.
Testing by ELISA. Commercially available qualitative solid phase antibody capture ELISA kits, which detected BRSV-, IBRV-, PI3V-, and BVDV-specific IgG, were obtained from a single source. a The standardization of these ELISA kits for the detection of seroconversion based on single-dilution testing of acute and convalescent serum pairs has been described previously. 9 The standardization procedure involved the determination of the rise in the sample/ positive (S/P) ratio (calculated according to the formula S/P ratio ϭ 100 ϫ corrected optical density [COD] of sample/ COD of positive reference serum) equivalent to a 4-fold rise Table 1 . Percentage increase in the sample/positive ratio equivalent to a 4-fold rise in antibody titer for standardization of 5 batches of BVDV-, 4 batches of BRSV-and PI3V-, and 3 batches of IBRV-antibody ELISA kits for quantitative use at a serum dilution of 1/100. in ELISA titer as determined by end-point titration. 9 Serum pairs that had an increase in S/P ratio equal to or greater than this value were considered to have seroconverted. Each batch of ELISA plates obtained from the manufacturer was standardized before use to determine this value.
All serum pairs were initially tested at a single serum dilution of 1/100 on each of the 4 kits as previously described, 9 and a software package b linked to the plate reader was used to calculate the COD, the S/P ratio, and the change in S/P ratio between acute and convalescent samples.
Based on the S/P ratio of the acute and convalescent sera and the difference between these 2 values, each serum pair was assigned 1 of 3 results. Those with an increase in S/P ratio representing a 4-fold or greater rise in titer to a given virus were considered to have seroconverted to that virus. Paired sera with an increase in S/P ratio less than this value but where the COD of the acute sample was Ͻ0.1 were considered to be inconclusive because their serologic status may have changed from seronegative to seropositive during the sampling period. All other pairs were assigned a negative result.
Two serum pairs that gave an inconclusive result for BVDV, 1 serum pair that gave an inconclusive result for IBRV, and 4 serum pairs that gave an inconclusive result for BRSV were unavailable for further testing. With these exceptions the acute and convalescent samples of each pair of sera giving an inconclusive result were retested qualitatively at a serum dilution of 1/25, according to the manufacturer's instructions, and the COD was recalculated. Those pairs that changed from seronegative to seropositive, based on the manufacturer's positive/negative threshold (PNT) of 0.2 for BRSV, PI3V, and IBRV and 0.250 for BVDV, were redesignated as positive. Those that did not show seroconversion in this way were redesignated as negative.
Correlation between ELISA results and VN and HI results. To examine the sensitivity and specificity of the ELISAs, some of the paired sera were also tested by VN or HI. A total of 72, 76, and 72 serum pairs were tested by VN to detect seroconversion to BVDV, IBRV, and BRSV, respectively. HI testing was performed on 73 serum pairs to detect seroconversion to PI3V.
VN and HI were performed as previously described. 9 VN titers Ն 1/4 and HI titers Ն 1/8 were considered positive. A change from seronegative to seropositive or a 4-fold or greater rise in titer between acute and convalescent samples was interpreted as indicating seroconversion.
Results
Standardization of ELISA kits. A total of 5 batches of BVDV kits, 4 batches of BRSV and PI3V kits, and 3 batches of IBRV kits were standardized for quantitative testing at a serum dilution of 1/100. Results of the standardization of these batches are given in Table  1 . The BVDV and IBRV kits yielded consistent results, with the change in S/P ratio equivalent to a 4fold rise in titer being within the range 31.0-35.0% in both cases. In contrast, the values for the BRSV and PI3V kits were 21.0-56.0% and 23.0-46.0%, respectively.
Testing by ELISA. The minimum S/P ratio in all four tests when serum pairs were tested at a serum dilution of 1/100 was zero. The maximum S/P ratio (and the COD value from which it was derived) obtained using the BVDV, BRSV, PI3V, and IBRV kits were 146.5% (1.49), 176.6% (1.65), 174.47% (1.27), and 182.7% (2.11), respectively. The changes in S/P ratio between acute and convalescent serum samples detected using the BVDV kit ranged from a decrease of 97.7% (Ϫ97.7%) to an increase of 74.1%. The corresponding values for the BRSV, PI3V, and IBRV kits were Ϫ114.8% to 127.2%, Ϫ95.9% to 151.7%, and Ϫ160.9% to 120.9%, respectively. Initial testing of the sera at a serum dilution of 1/100 detected seroconversion to BVDV in 22 pairs of sera, to BRSV in 60 pairs, to PI3V in 67 pairs, and to IBRV in 31 pairs ( Table  2) . Following testing at a serum dilution of 1/25 of samples that produced inconclusive results, the number of pairs in which seroconversion was detected increased to 45, 107, 77, and 42 for BVDV, BRSV, PI3V, and IBRV, respectively ( Table 2) .
No seroconversion was detected in 369 (65.4%) of the 564 paired sera tested. Seroconversion to 1 of the 4 viruses was detected in 142 (25.2%) paired sera, to 2 of the 4 viruses in 34 (6.0%) paired sera, to 3 of the 4 viruses in 15 (2.7%) paired sera, and to all 4 viruses in 4 (0.7%) paired sera (Table 3) .
One or more seroconversions were detected in 88 (60.7%) of the 145 outbreaks investigated. In 47 Table 2 . Results* from 564 serum pairs tested by ELISA for seroconversion to BVDV, BRSV, PI3V, and IBRV. Serum pairs were initially tested quantitatively at a serum dilution of 1/100. Those giving an inconclusive result were retested qualitatively at a serum dilution of 1/25. Those showing a change in serologic status from seronegative to seropositive were redesignated as positive. (53.4%) of these 88 outbreaks, seroconversion to only 1 virus was detected. Seroconversion to 2 viruses was detected in 29 (33.0%) outbreaks, to 3 viruses in 9 (6.2%) outbreaks, and to 4 viruses in 3 (3.4%) outbreaks ( Table 4 ).
Comparison of ELISA results with VN and HI results. VN titers of the serum samples tested ranged from negative (Ͻ1/4) to Ն1/12,288, 1/4,096, and 1/384, respectively, for BVDV, BRSV, and IBRV. The corresponding range for HI titers to PI3V ranged from negative (Ͻ1/8) to 1/4,096. The change in BVDV VN titers of the serum samples tested ranged from a 4-fold decrease to a 128-fold increase between acute and convalescent serum samples. The corresponding range of changes in BRSV and IBRV VN and PI3V HI titers are an 8-fold decrease to a 128-fold increase, a 16-fold decrease to a 128-fold increase, and a 6-fold decrease to a 48-fold increase, respectively.
The sensitivity, specificity, and overall correlation between ELISA results and VN results for BVDV were 92%, 89%, and 90%, respectively. The corresponding figures for BRSV and IBRV were 95%, 92%, and 93% and 100%, 91%, and 93%, respectively. The sensitivity, specificity and overall correlation between ELISA results and HI results were 100%, 86%, and 90% ( Table 5 ).
Discussion
The results of the standardization of multiple batches of ELISA kits for quantitative use at a serum dilution of 1/100 were surprising in that the increase in S/P ratio corresponding to a 4-fold rise in titer to BVDV and IBRV remained relatively constant among different batches of kits, whereas the figure for both BRSV and PI3V was more variable, ranging from 21.0% to 56.0% and from 23.0% to 46.0%, respectively. The reason for this variation is unknown, but it may reflect variations in conjugate, substrate, or stopping solution among batches. 5 The necessity of standardizing quantitative single-dilution ELISAs each time a new batch of kits is introduced has been previously emphasized, 20 and these findings reinforce this point.
Serologic diagnosis of infection may be made by demonstrating a change in serologic status from seronegative to seropositive or a significant (4-fold) rise in titer when acute and convalescent serum pairs are tested. Although a given serum pair may satisfy both of these criteria, others may satisfy only one or the other, and it is therefore essential that any diagnostic test correctly identifies both eventualities.
A wide range of COD values and resultant S/P ratios were obtained with all tests when sera were tested at a dilution of 1/100. Correspondingly, a wide range of changes in S/P ratio between acute and convalescent samples were also detected. Decreases in S/P ratio between serum pairs indicate waning titers of maternally derived antibody or the decline of an active antibody response following an earlier infection.
The ELISA kits used in this work were supplied by the manufacturer for qualitative testing at a serum dilution of 1/25, with each serum being scored as antibody positive or antibody negative based on whether or not the COD exceeds the positive/negative threshold (PNT). Ideally, the kits would have been standardized for quantitative use at this same dilution, which would have allowed the detection of seroconversion in serum pairs showing a change in serologic status from seronegative to seropositive or a 4-fold rise in titer by examination of the COD and S/P ratio, respectively, of the acute and convalescent samples obtained at a single test dilution. However, the results of our initial standardization experiments 9 indicated that the linear relationship between ELISA titer and S/P ratio was in fact strongest at a serum dilution of 1/100, and therefore this dilution was used in all quantitative testing. Because the PNT for each test was defined for use at a serum dilution of 1/25 rather than 1/100, it was not possible to conclusively identify all those serum pairs whose serologic status changed from seronegative to seropositive over the sampling period. To identify such serum pairs, an inconclusive result was assigned to serum pairs where the increase in the S/P ratio was insufficiently large to confirm a 4-fold increase in titer, but the COD of the acute sample was Ͻ0.1, suggesting that it might give a seronegative result if retested at a serum dilution of 1/25. The upper COD value of 0.1 represents 50% of the PNT value of the BRSV, PI3V, and IBRV kits. In practice, the COD values of the majority of acute serum samples from serum pairs assigned an inconclusive result were much lower (Ͼ70% were Ͻ0.02). These serum pairs were retested at a serum dilution of 1/25, and those that showed a change from seronegative to seropositive were reassigned a positive result. Of a total of 2,256 initial tests performed on serum pairs, only 142 (6.3%) required retesting in this way ( Table 1 ). The highest number of inconclusive results arose with the BRSV kits due to the large increase in S/P ratio necessary to demonstrate a 4-fold rise in titer when serum pairs were tested with the third and fourth batches of BRSV kits.
A total of 180 seroconversions were detected on initial testing at a serum dilution of 1/100. A further 91 seroconversions were detected when tests giving inconclusive results were repeated at a serum dilution of 1/25, confirming the importance of including this result category ( Table 1) .
In a previous survey in Northern Ireland, 13 researchers found serologic evidence of infection with BRSV and PI3V on over 97% of farms, and it is therefore not surprising that the highest incidence of seroconversion detected in serum pairs was to BRSV (19.0%), followed by PI3V (13.7%). Seroconversion to BVDV was found in 8.0% of serum pairs examined. The role of BVDV in respiratory disease still requires clarification. Although the virus has been isolated from cases of respiratory disease, 2,15 experimental work has failed to demonstrate the pneumopathogenicity of such isolates. 14 In one survey of the association between viral infections and respiratory disease in calves, researchers failed to find an association with BVDV infection, 6 whereas in another similar survey researchers found that a significant association did exist. 21 Seroconversions to IBRV were least common; they were detected in 7.4% of serum pairs. Virulent strains of bovine herpesvirus 1 associated with bovine respi-ratory disease, which has been a problem in Great Britain since the mid-1970s, 7 have only emerged in Northern Ireland in the past few years, with a increasing number of isolates being identified in this laboratory (data not shown).
Of the 195 serum pairs in which seroconversion was detected, 25% demonstrated seroconversion to Ն2 viruses. When these results were analyzed by outbreak, 46.6% of outbreaks showed serologic evidence of the involvement of Ն2 viruses, highlighting the multifactorial nature of bovine respiratory disease. Multiple seroconversions to respiratory viruses have been reported previously. 4, 11, 18 Unfortunately, insufficient history was supplied with many of the submissions, precluding further analysis of data by herd type or age.
Acute infection with BVDV is recognized to have a broad immunosuppressive effect, including a reduction in number and/or functionality of B and T lymphocytes, polymorphonuclear lymphocytes, and alveolar macrophages. 3, 17, 19, 22 This immunosuppressive effect has been shown experimentally to potentiate infections with other viral 15 and bacterial 16 respiratory pathogens. Although BVDV accounted for 16.6% of all seroconversions detected, seroconversion to BVDV alone was detected in Ͻ4% of outbreaks, more commonly being found in association with Ն1 other virus ( Table 4 ). Seroconversion to one or more other viruses was found in 69.9% of animals that showed seroconversion to BVDV. In a previous survey, 18 an even higher percentage (92%) of BVDV infections associated with respiratory disease were associated with multiple virus infections. These findings support the hypothesis that the primary role of BVDV in these outbreaks is one of immunosuppression rather than as a primary pathogen.
The sensitivity, specificity, and overall correlation of the ELISA results compared with VN and HI results were high, with overall correlation ranging from 90% for BVDV to 93% for BRSV and IBRV. These results are similar to those obtained when VN and ELISA were compared for detection of seroconversion using end-point titration of each sample by ELISA. 8, 23 A total of 19 (6.4%) of 295 serum pairs tested demonstrated seroconversion by ELISA but not by VN or HI. Only 3 serum pairs demonstrated seroconversion by VN but not by ELISA. Following natural infections, VN titers begin to rise before the ELISA titer, which may reflect the ELISA being less effective at detecting low-affinity antibodies early in infection, at recognizing IgG-but not IgM-isotype antibodies, or both. 10, 12, 23 These divergent results are supported by the fact that virus-specific IgM was detected by IFAT in 9 of the 19 ELISApositive/VN-negative serum pairs (data not shown).
In conclusion, this ELISA system is suitable for the rapid, simultaneous testing of serum pairs for the de-tection of seroconversion to multiple viruses, and the results obtained are in close agreement with those obtained by VN and HI. The results demonstrate the frequency with which multiple viral infections occur in outbreaks of respiratory disease and suggest that BVDV may primarily be involved as an immunosuppressive agent.
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